Taro Pharmaceutical Industries Ltd.

Taro Receives FDA Approval for Fluorouracil Topical Cream USP, 5%

Published in Cancer Weekly, March 23rd, 2010

Taro Pharmaceutical Industries Ltd. ("Taro" or the "Company," Pink Sheets: TAROF) reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application ("ANDA") for Fluorouracil Topical Cream USP, 5% ("fluorouracil cream").

Taro's fluorouracil cream is a prescription pharmaceutical product used for topical treatment of multiple actinic or solar keratoses and superficial basal cell carcinomas, and is bioequivalent to Efudex® Topical Cream 5% of Valeant Pharmaceuticals International. According to industry sources, Efudex® Topical Cream 5% had annual U.S. sales in 2009 of approximately $70 million.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2010-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry